Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Cutaneous squamous cell carcinoma is a malignant non-melanoma skin cancer arising from epidermal squamous cells. As per Martina Catalano et al. (2024), it is the second most prevalent non-melanoma skin cancer globally, comprising approximately 20% of cutaneous malignancies. According to the cutaneous squamous cell carcinoma epidemiology forecast by Expert Market Research, disease burden remains substantial, supporting continued epidemiological monitoring worldwide.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Cutaneous Squamous Cell Carcinoma – Number of Cases by Year

Read more about this report - Request a Free Sample

Cutaneous Squamous Cell Carcinoma Epidemiology Forecast Report Coverage

Expert Market Research's “Cutaneous Squamous Cell Carcinoma Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of cutaneous squamous cell carcinoma. It projects the future incidence and prevalence rates of cutaneous squamous cell carcinoma cases across various populations. The study covers age, gender, and type as major determinants of cutaneous squamous cell carcinoma population. The report highlights patterns in the prevalence of cutaneous squamous cell carcinoma over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of cutaneous squamous cell carcinoma in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Cutaneous Squamous Cell Carcinoma Understanding: Disease Overview

Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer that develops from malignant transformation of keratinocytes, particularly after cumulative ultraviolet (UV) radiation-induced DNA damage. It most often occurs in sun-exposed areas such as the head, neck, arms, and hands, although it can develop anywhere on the skin. cSCC may arise from precancerous lesions such as actinic keratosis and can appear as a rough, scaly patch, firm growth, or nonhealing sore. Clinically, it includes invasive squamous cell carcinoma, squamous cell carcinoma in situ, and histologic variants with different levels of differentiation and aggressiveness.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Country

India

High-Risk Population

Older adults, immunosuppressed individuals, organ-transplant recipients, and people with substantial cumulative UV exposure

Key Diagnostic Method

Skin examination and biopsy-Clinical examination followed by histopathologic confirmation is central to diagnosis

Major Risk Factor

Cumulative ultraviolet (UV) radiation exposure. Chronic exposure is a major etiologic factor in cSCC.

Major gap in the market

Delayed detection and limited access to specialist dermatologic assessment. These factors can contribute to diagnosis at more advanced stages.

Cutaneous Squamous Cell Carcinoma Epidemiology Perspective

The cutaneous squamous cell carcinoma epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the cutaneous squamous cell carcinoma epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cutaneous squamous cell carcinoma and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Martina Catalano et al. (2024), cutaneous squamous cell carcinoma (cSCC) is the second most prevalent non-melanoma skin cancer worldwide, accounting for approximately 20% of cutaneous malignancies.

Gender-Specific Cases of the Disease

According to Yumeng Pan et al. (2025), males accounted for 56.47% of global squamous cell carcinoma cases, indicating a higher disease burden among males than females.

Age-Specific Cases of the Disease

As per Yumeng Pan et al. (2025), the global burden of squamous cell carcinoma increased substantially among older adults between 1990 and 2021, with incidence increasing by 322.77%.

Ethnicity-Wise Cases of the Disease

According to Shehnaz Ahmed et al. (2026), cSCC was substantially more common in White populations in England, with an age-standardized incidence rate of 61.8 per 100,000, compared with 4.55 among Asian and 4.73 among Black populations.

Mortality and Survival Analysis of the Disease

According to Martina Catalano et al. (2024), 3–7% of patients develop locally advanced or metastatic cSCC, while metastatic disease carries substantial mortality. The reported mortality risk associated with metastasis was 2.8%.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Conventional cSCC

Includes the conventional/classic form of cSCC, representing the primary histopathologic presentation.

Verrucous Carcinoma

A well-differentiated variant of cSCC characterized by a verrucous growth pattern.

Acantholytic Cutaneous Squamous Cell Carcinoma

A histopathologic variant characterized by acantholysis and associated with distinct microscopic features.

Other

Includes spindle cell (sarcomatoid), desmoplastic, clear cell, basosquamous, adenosquamous, and metaplastic variants of cSCC.

Cutaneous Squamous Cell Carcinoma – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Cutaneous Squamous Cell Carcinoma Epidemiology

The cutaneous squamous cell carcinoma epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to Rina Jiang et al. (2024), the estimated annual incidence of cSCC in the United States exceeds 1 million cases. The reported increase has been associated with cumulative ultraviolet radiation exposure, an aging population, systemic immunosuppression, and expanded skin cancer screening.

Germany

In Germany, the cSCC burden is influenced by epidemiological factors including advanced age, cumulative lifetime ultraviolet radiation exposure, sun-sensitive skin, and immunosuppression, particularly among individuals with solid organ transplantation.

France

In France, prevalence is influenced by advanced age, lifetime ultraviolet radiation exposure, sun-sensitive skin, and immunosuppression. Additional factors associated with cSCC development include tobacco smoking, therapeutic ionizing radiation, and certain skin conditions.

Italy

The epidemiological burden in Italy is influenced by advanced age and cumulative ultraviolet radiation exposure. Immunosuppression, sun-sensitive skin, tobacco smoking, and therapeutic ionizing radiation are additional factors associated with cSCC development.

Spain

According to N.F. Fernández-Martínez et al. (2026), the age-standardized incidence rate of non-melanoma skin cancer excluding basal cell carcinoma in Spain was estimated at 9.1 cases per 100,000 population in 2022, with most cases corresponding to cSCC.

United Kingdom

According to Birgitta van Bodegraven et al. (2024), 45,585 cSCC cases were recorded in England in 2020. Among 415,236 first-ever cSCC tumors diagnosed during 2004–2020, the median age at diagnosis was 78 years and 61.7% of patients were male.

Japan

According to Yasuyoshi Sato et al. (2023), approximately 2,507 cutaneous SCC cases were recorded in Japan during 1987–1991, representing 28.8% of cutaneous malignancies, with an estimated incidence of approximately 2.5 cases per 100,000 people annually.

India

In India, cSCC epidemiology is influenced by factors such as lifetime ultraviolet radiation exposure, advanced age, sun-sensitive skin, and immunosuppression. Other factors associated with disease development include certain skin conditions, tobacco smoking, and therapeutic ionizing radiation.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

The regional cSCC landscape presents opportunities to improve early detection, risk stratification, and access to specialized dermatologic care across the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India. A major unmet need is the timely identification of lesions among older adults, immunosuppressed patients, and individuals with substantial cumulative UV exposure. Expanding dermatologist access, improving awareness of suspicious skin lesions, and strengthening biopsy-based diagnostic pathways could increase case detection. In advanced disease, continued adoption and development of immunotherapies and multidisciplinary treatment approaches represent emerging opportunities.

Cutaneous Squamous Cell Carcinoma: Treatment Overview

Cutaneous squamous cell carcinoma treatment depends on tumor size, location, depth, recurrence risk, and whether the cancer has spread. Surgical excision is commonly used for localized tumors, while Mohs micrographic surgery is particularly useful for selected high-risk tumors or anatomically sensitive sites. Curettage and electrodesiccation, cryosurgery, and radiation therapy may be considered for selected tumors when appropriate. Advanced or unresectable cSCC may require systemic immunotherapy, including programmed cell death protein 1 (PD-1) inhibitors. Treatment may involve multidisciplinary care when tumors are locally advanced, recurrent, or metastatic.

Key Questions Answered

  • What is the current and projected burden of cutaneous squamous cell carcinoma across the 8 major markets?
  • Which countries across the 8 major markets account for the highest cutaneous squamous cell carcinoma patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of cutaneous squamous cell carcinoma across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of cutaneous squamous cell carcinoma across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of cutaneous squamous cell carcinoma across the 8 major markets?
  • How do major comorbidities and risk factors influence cutaneous squamous cell carcinoma epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of cutaneous squamous cell carcinoma across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the cutaneous squamous cell carcinoma landscape across the 8 major markets?
  • Which therapeutic areas linked to cutaneous squamous cell carcinoma are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the cutaneous squamous cell carcinoma epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on cutaneous squamous cell carcinoma epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for cutaneous squamous cell carcinoma across the 8 major markets?

Scope of the Cutaneous Squamous Cell Carcinoma Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cutaneous squamous cell carcinoma based on several factors.
  • Cutaneous Squamous Cell Carcinoma Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The cutaneous squamous cell carcinoma report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Cancer Supportive Care Drugs Market

Cancer Therapeutics Market

Cancer Tumor Profiling Market

Cancer Screening Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us